Mirxes Co-Founder and CEO Dr Zhou Lihan
Mirxes, an RNA technology firm headquartered in Singapore, has raised US$40 million in structured financing from R-Bridge Healthcare Fund, which is owned by CBC Group, according to reports.
The funding will fuel global expansion, primarily in high-growth Asian markets, including Southeast Asia, China, and Japan.
Also Read: ‘We aim to make early cancer detection accessible on a global scale’: Mirxes CEO
The latest injection comes about a year and a half after Mirxes secured US$50 million from existing and new investors, Beijing Fupu, EDBI, Mitsui & Co., NHH Venture Fund, and the Agency for Science, Technology and Research.
Established in June 2014 as a spin-off from A*STAR, Mirxes was conceptualised and developed by co-founders Dr Zhou Lihan, Prof. Too Heng-Phon, and Dr Zou Ruiyang.
The company makes early cancer detection solutions accessible globally. Its flagship initiative, Project CADENCE (Cancer Detected Early caN be CurEd), leverages its RNA technology platform, deep expertise in PCR diagnostics, and population-scale next-generation sequencing (NGS) capabilities to create a blood-based multi-cancer early detection test to alleviate cancer burden, save lives and reduce healthcare costs.
Last June, its fully-owned subsidiary, Mirxes Japan, secured a grant of up to 20 million yen (US$127,000) from the Japan External Trade Organization (JETRO). The grant will support the development and validation of a new non-invasive cancer biomarker screening test service specifically for the Japanese market.
Also Read: Harnessing the power of AI to help improve gastric cancer detection
Previously, Mirxes raised US$77 million in a Series C financing round led by CR-CP Life Science Fund and joined by global healthcare investment firm Rock Springs Capital, Charoen Pokphand Group (Thailand) and EDBI.
The post Mirxes raises US$40M to expand early cancer detection solution into SEA, Japan, China appeared first on e27.